This study aims to assess the ability of 18F-FDG PET/CT metabolic parameters to predict PD-L1 expression in NSCLC patients and explore whether metabolic heterogeneity can inform immunohistochemical responses, supporting immunotherapy decisions. The gene discussed is CD274; the disease is non-small cell lung carcinoma.